# An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

> **NCT02577406** · PHASE3 · COMPLETED · sponsor: **Celgene** · enrollment: 319 (actual)

## Conditions studied

- Leukemia, Myeloid
- Isocitrate Dehydrogenase

## Interventions

- **DRUG:** AG-221
- **OTHER:** BSC
- **DRUG:** Azacitidine
- **DRUG:** Low-dose cytarabine (LDAC)
- **DRUG:** Intermediate-dose cytarabine (IDAC)

## Key facts

- **NCT ID:** NCT02577406
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-30
- **Primary completion:** 2020-03-17
- **Final completion:** 2024-03-25
- **Target enrollment:** 319 (ACTUAL)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02577406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02577406, "An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02577406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*